BET1 and amyotrophic lateral sclerosis: However, further studies—ideally on cohorts with defined genetic defects such as Charcot–Marie–Tooth neuropathies and hereditary forms of amyotrophic lateral sclerosis—are needed to elucidate the varying impact of BET1 in the formation of neurogenic targets more precisely.